All canine diagnoses

Your dog was diagnosed with Oral Malignant Melanoma. Most common malignant oral tumour in dogs. Represents ~30-40% of oral malignancies. Highly aggressive with early metastasis to regional lymph nodes and lungs. Compare 5 treatment options for dogs including Surgical Excision (Mandibulectomy/Maxillectomy), Surgery + Adjuvant Carboplatin, Coarse-Fractionated (Hypofractionated) Radiation Therapy — with survival times, costs, and what to expect during treatment.

🐕

Oral Malignant Melanoma

WHO Stage I-IV

BreedsCocker SpanielMiniature PoodleGolden RetrieverGordon SetterChow ChowScottish TerrierDachshund
canine

Melanocytic

About This Cancer

Oral malignant melanoma arises from melanocytes, the pigment-producing cells found in the lining of the mouth. It is the most common malignant tumour of the oral cavity in dogs and is among the most aggressive cancers encountered in canine oncology. The tumour can appear as a pigmented (dark) or amelanotic (non-pigmented) mass on the gums, palate, tongue, or lips. It typically invades underlying bone and spreads early to regional lymph nodes and lungs — by the time of diagnosis, metastasis has often already occurred. The WHO staging system, based on tumour size, is one of the strongest predictors of survival. Treatment usually involves aggressive surgery, often requiring partial removal of the jaw. A melanoma vaccine (Oncept) is available and is used as an adjunct to surgery and other treatments, though its precise survival benefit continues to be studied.

WHO Clinical Staging for Canine Oral Melanoma

Based on tumour diameter, lymph node involvement, and distant metastasis

Stage ITumour <2 cm diameter, N0, M0
Stage IITumour 2-4 cm diameter, N0, M0
Stage IIITumour >4 cm diameter and/or N+, M0
Stage IVAny T, any N, M1 (distant metastasis)
Prognostic Factors(5)
Stage at diagnosisMST decreases sharply with advancing stage: Stage I ~17-18 months, Stage II ~5-6 months, Stage III ~3 months with surgery alone(Freeman et al., 2003)
Amelanotic histologyAmelanotic melanomas may behave more aggressively. Mitotic index is the strongest histological prognostic factor.(Smedley et al., 2011)
Mitotic indexHigh mitotic index (>4 per 10 HPF) associated with significantly shorter survival(Smedley et al., 2011)
Bone involvementBone lysis at presentation associated with worse prognosis and poorer response to radiation(Magalhaes et al., 2022)
Ki-67 indexKi-67 >19.5% associated with shorter survival; most accurate prognostic marker across melanocytic neoplasms(Smedley et al., 2011)
Minimum Workup(6 steps)
1Fine-needle aspirate or incisional biopsy with histopathology
2Regional lymph node cytology (mandibular, retropharyngeal)
3Thoracic radiographs (3-view) or CT for pulmonary metastasis
4CT or MRI of the head for local extent and bone involvement
5Complete blood count and biochemistry panel
6Urinalysis

Median Survival Time Comparison

How long the average patient survives with each treatment

Bar opacity reflects evidence strength
Surgical Excision (Mandibulectomy/Maxillectomy)
~17 mo (5–34)
Surgery + Adjuvant Carboplatin
~13 mo (11–15)
Coarse-Fractionated (Hypofractionated) Radiation Therapy
~7.7 mo (5.7–13.8)
Surgery ± RT + Oncept Melanoma Vaccine
See notes
Palliation / Comfort Care
~3 mo (1–5)
Reading this page: MST (Median Survival Time) is how long the average patient survives with a given treatment. ORR (Overall Response Rate) is the percentage of patients whose tumour shrank or disappeared. CR = Complete Response (tumour gone); PR = Partial Response (tumour shrank). Hover over any abbreviation for a quick explanation.
Strength of Evidence

Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.

StrongLarge published studies with strong agreement among veterinary oncologists.
ModerateWidely used in clinical practice, but supported by smaller or retrospective studies.
IndirectEvidence comes from a different tumour type or species and has been applied here.
LimitedVery little published data is available for this specific treatment.

Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.